Tislelizumab plus chemo for early-stage NK/T-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NK/T-cell lymphoma, stage I or II.
- You are between 18 and 70 years old.
- You are able to handle daily activities with little to no help (ECOG score 0-2).
- You have not received any previous chemotherapy, immunotherapy, or targeted therapy for this lymphoma.
- You do not have a serious infection or a condition called hemophagocytic syndrome or DIC.
- You do not have an active autoimmune disease or a known allergy to the drugs in this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy as a first treatment for people with stage IIIB or IIIC non-small cell lung cancer. The goal is to see if this approach can shrink the tumor before any other treatment.
This trial tests whether adding a medicine called tislelizumab to radiation works better than radiation alone for newly diagnosed nasal (nasal-type) NK/T-cell lymphoma. If you qualify, it may help control the cancer and improve outcomes by using both treatments together.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new ORR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.